Advertisement
Screener

ENTRADA THERAPEUTICS, INC. (TRDA) Operating Lease Right-of-Use Assets

2.8 / 5 stars · 68/120 Roast Me

ENTRADA THERAPEUTICS, INC. Operating Lease Right-of-Use Assets

ENTRADA THERAPEUTICS, INC. (TRDA) had Operating Lease Right-of-Use Assets of $57.04 million as of 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Balance Sheet › Assets › Assets, Noncurrent

us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05

  • 2026-06-30: Operating Lease, Right-of-Use Asset $57.04M.
  • 2026-03-31: Operating Lease, Right-of-Use Asset $58.76M.
  • 2025-12-31: Operating Lease, Right-of-Use Asset $60.45M.
  • 2025-09-30: Operating Lease, Right-of-Use Asset $62.12M.
Period endOperating Lease, Right-of-Use Asset
2026-06-30$57.04M
10-Q · filed 2026-08-05
2026-03-31$58.76M
10-Q · filed 2026-05-07
2025-12-31$60.45M
10-Q · filed 2026-08-05
2025-09-30$62.12M
10-Q · filed 2025-11-06
2025-06-30$65.68M
10-Q · filed 2025-08-06
2025-03-31$68.42M
10-Q · filed 2025-05-08
2024-12-31$71.12M
10-K · filed 2026-02-26
2024-09-30$73.77M
10-Q · filed 2024-11-05
2024-06-30$76.39M
10-Q · filed 2024-08-13
2024-03-31$78.96M
10-Q · filed 2024-05-07
2023-12-31$81.49M
10-K · filed 2025-02-27
2023-09-30$84.02M
10-Q · filed 2023-11-07
2023-06-30$88.28M
10-Q · filed 2023-08-08
2023-03-31$14.25M
10-Q · filed 2023-05-10
2022-12-31$25.34M
10-K · filed 2024-03-13
2022-09-30$27.38M
10-Q · filed 2022-11-07
2022-06-30$29.40M
10-Q · filed 2022-08-11
2022-03-31$31.41M
10-Q · filed 2022-05-12
2022-01-01$33.00M
10-Q · filed 2022-08-11
2021-12-31$0.00
10-Q · filed 2022-08-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55